Form 4: Director Charles Theuer Acquires 50,000 Stock Options

Charles Theuer, a Director at 4D Molecular Therapeutics, Inc., has been granted 50,000 stock options as part of the company's non-employee director compensation program.

Summary

• Director Charles Theuer acquired 50,000 stock options in 4D Molecular Therapeutics, Inc. on June 17, 2026.
• These options were granted automatically under the company's non-employee director compensation program.
• The stock options have an exercise price of $9.42 and an expiration date of June 16, 2036.
• Vesting of the options will occur in stages, with 1/3 vesting on June 17, 2027, and the remainder vesting monthly until fully vested on June 17, 2029, contingent on continued service.
• Full vesting is also triggered upon a Change in Control event.
• Following this transaction, Charles Theuer directly beneficially owns 50,000 shares represented by these options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation grant to a director rather than a significant financial event or strategic shift.

Positives

• Director compensation aligns with long-term company performance through stock options.
• The grant of options indicates continued confidence in the company's future prospects by its directors.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• The value of the options is contingent on the future stock price performance of 4D Molecular Therapeutics, Inc.

Risks

• The value of the stock options is subject to market volatility and the company's future performance.
• Continued service is a condition for vesting, meaning the director could forfeit unvested options if service is terminated.

Future Outlook

The stock options are exercisable at $9.42 and vest over a period extending to June 17, 2029, with full vesting also possible upon a Change in Control. The ultimate value realized will depend on the company's stock performance.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and therapeutics sector, aligning executive incentives with shareholder value creation and long-term growth.

Stakeholder Impact

• Shareholders: The grant of options to directors is a standard compensation practice and does not immediately impact share count or dilution, but could in the future if options are exercised. It aligns director interests with long-term stock performance.
• Employees: This filing does not directly impact employees, but the compensation structure for directors can be indicative of the company's overall compensation philosophy.
• Management: The filing confirms a standard compensation arrangement for a director.

Next Steps

• Director Charles Theuer will continue to serve the company, subject to the vesting schedule of the stock options.
• The company will continue to operate under its non-employee director compensation program.

Key Dates

Keywords

Form 4, SEC Filing, Stock Options, Director Compensation, 4D Molecular Therapeutics, FDMT, Beneficial Ownership, Vesting Schedule, Insider Trading